Skip to main content

Dako Signs Another CDx Agreement with Amgen

NEW YORK (GenomeWeb) – Dako, an Agilent Technologies company, today announced it has signed an additional collaboration with Amgen to develop a companion diagnostic for an unspecified Amgen cancer drug candidate.

In an email to GenomeWeb, Agilent declined to provide additional details about the agreement.

The deal builds on agreements from 2012 between the two companies, under which Dako was developing several companion diagnostics for drugs from Amgen.

Dako also has inked similar companion diagnostic agreements with several pharma firms over the past few years including AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Genentech.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.